<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884920</url>
  </required_header>
  <id_info>
    <org_study_id>Hashmi5767</org_study_id>
    <nct_id>NCT03884920</nct_id>
  </id_info>
  <brief_title>Effective Enhancement of Glucose Tolerance and Prevention of Diabetes Mellitus Type 2 by Polyherbal Formulation</brief_title>
  <acronym>Phase-1</acronym>
  <official_title>Impaired Glucose Tolerance and Prevention of Diabetes Mellitus Type 2 by Polyherbal Formulation of Eastern Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Islamia University of Bahawalpur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Islamia University of Bahawalpur</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary protocol to this study is to develop a natural remedy to prevent diabetes mellitus in
      pre-diabetic state and elaborate the effectiveness of polyherbal formulation for carrying out
      Phase-II, III and IV. It also aimed at to see the level of difference of glucose tolerance
      and impaired fasting glucose and impaired glucose tolerance between pre-diabetic and diabetic
      to evaluate the potential benefit for treatment of insulin resistance and sensitivity. To see
      the for prevention of Diabetes Mellitus (DM) and stopping / delaying the onset of DM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a clinical trial study to evaluate the potential of prevention in pre-diabetics
      and to prevent onset of diabetes mellitus. For this purpose, volunteers will be enrolled in
      the study by observing the Helsinki Declaration for clinical trials.

      volunteers will be screened for the impaired glucose tolerance or impaired fasting glucose or
      at risk to develop diabetes mellitus type 2.

      On screening, pre-diabetics and early onset diabetics with no previous history of treatment
      etc will be grouped into A and B.

      Biochemical evaluations will be carried out at base line and followed by three weeks
      intervention and evaluation of biomarkers and at sixth week for further evaluation.

      Collected data will be evaluated for primary out comes and secondary out come. statistical
      analysis will be done.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Actual">May 20, 2019</completion_date>
  <primary_completion_date type="Actual">May 5, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting Glucose Tolerance (FGT)</measure>
    <time_frame>six weeks</time_frame>
    <description>enhancement of fasting glucose tolerance (&lt;100mg/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose Tolerance (GT)</measure>
    <time_frame>six weeks</time_frame>
    <description>enhancement of oral glucose tolerance (&lt;140mg/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HB-A1c</measure>
    <time_frame>six week</time_frame>
    <description>improvement in glycated hemoglobin (HB-A1c) percentage &lt;6%,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid Profile</measure>
    <time_frame>six weeks</time_frame>
    <description>serum Cholesterol level (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Profile</measure>
    <time_frame>Six Weeks</time_frame>
    <description>Serum Triglycerides (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Profile</measure>
    <time_frame>Six week</time_frame>
    <description>Serum Low Density Lipids (LDL) (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Profile</measure>
    <time_frame>six week</time_frame>
    <description>Serum High Density Lipids (HDL) (mg/dl)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Liver Functions</measure>
    <time_frame>six week</time_frame>
    <description>Serum Glutamate pyruvate transaminase (SGPT) (mg/dl)</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver Function</measure>
    <time_frame>six week</time_frame>
    <description>serum glutamate oxaloacetate transaminase (SGOT)(mg/dl)</description>
  </other_outcome>
  <other_outcome>
    <measure>Liver Function</measure>
    <time_frame>six week</time_frame>
    <description>Alkaline phosphatase (ALP)</description>
  </other_outcome>
  <other_outcome>
    <measure>Kidney Function</measure>
    <time_frame>six week</time_frame>
    <description>Serum creatinine (mg/dl)</description>
  </other_outcome>
  <other_outcome>
    <measure>Kidney Function</measure>
    <time_frame>six week</time_frame>
    <description>Blood Urea Nitrogen (mg/dl)</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">57</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Pre Diabetes</condition>
  <arm_group>
    <arm_group_label>Group A Pre-diabetic placebo</arm_group_label>
    <description>Group of pre-diabetics receiving placebo BD for six weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B Pre-diabetic test</arm_group_label>
    <description>Group of Pre-diabetic receiving polyherbal / test candidate 900mg in two divided doses for six weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C Diabetic test</arm_group_label>
    <description>Early onset of Diabetes mellitus receiving polyherbal formulation 1800mg in two divided doses for six weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Polyherbal formulation</intervention_name>
    <description>Test candidate will be administered per oral before / with meal in two divided doses</description>
    <arm_group_label>Group B Pre-diabetic test</arm_group_label>
    <arm_group_label>Group C Diabetic test</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  community samples will be obtained from the area of Bahawalpur

          -  Model Town A, B, and

          -  remote areas of district Bahawalpur consisting of Khairpur Tamewali city population
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-59

          -  Impaired Fasting Glucose (100-125mg/dl)

          -  Impaired Glucose Tolerance (140-199mg/dl) 2h-75gm OGTT

          -  History of Diabetes in first degree relation with one condition

          -  At high risk with BMI &gt; 35%

          -  Early onset diabetic / accidental on screening (glucose &gt;200mg/dl)

        Exclusion Criteria:

          -  on renal dialysis;

          -  an acute or terminal illness or serious mental illness;

          -  history of recent coronary event within the last 12 months;

          -  a recent history of acute medical problem or admission to hospital;

          -  any other severe medical conditions that need intervention / treatment

          -  has poor short-term prognosis (expected death in &lt;2 years);

          -  is planning to travel for longer than 6 weeks during the 6-week intervention period;
             or

          -  is with compromised liver / kidney / cardiac function

          -  older patients of DM taking any form of medication / intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H A Sattar Hashmi, M.Phil</last_name>
    <role>Principal Investigator</role>
    <affiliation>scholar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr K A.Ansari, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>AP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University College of Conventional Medicine</name>
      <address>
        <city>Bahawalpur</city>
        <zip>63100</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Islamia University of Bahawalpur</investigator_affiliation>
    <investigator_full_name>Hafiz Abdul Sattar Hashmi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Impaired Fasting Glucose</keyword>
  <keyword>Impaired Glucose Tolerance</keyword>
  <keyword>2hr -75gm Oral Glucose Tolerance Test</keyword>
  <keyword>Diabetes Mellitus Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT03884920/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

